Clinical Outcomes of Palbociclib and Letrozole in PALOMA-2

Palbociclib plus letrozole clinical outcomes PALOMA-2

In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival by 13 months compared to letrozole alone (27.6 vs 14.5 months) with manageable hematologic toxicity and maintained quality of life, but did not demonstrate a significant overall survival benefit after 90 months of follow-up.

Abstract

The PALOMA-2 trial demonstrated that palbociclib plus letrozole significantly improved progression-free survival compared to placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer. Median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001), with consistent benefit observed across all patient subgroups including Asian patients (25.7 vs 13.9 months, HR 0.49, P=0.007) and those with low disease burden. Notably, PFS improvement occurred regardless of objective response status, with non-responders experiencing median PFS of 10.9 versus 5.6 months (HR 0.72, P=0.016). The treatment delayed time to subsequent chemotherapy by approximately 10 months (40.4 vs 29.9 months). However, after 90.1 months of follow-up, median overall survival was 53.9 versus 51.2 months (HR 0.96, P=0.34), showing no significant improvement.

The primary toxicity was hematologic, with grade 3-4 neutropenia occurring in 66.4% of patients (vs 1.4% with placebo), increasing to 89.2% in Asian populations. Despite this, febrile neutropenia remained rare (1.8-2.0%), and treatment discontinuation rates were low (9.7-12.2% vs 5.9%). Quality of life was maintained with no significant differences in FACT-Breast Total or EQ-5D scores between treatment arms, and pain scores significantly improved with palbociclib plus letrozole (P=0.0183). Neutropenia did not negatively impact quality of life measures.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Records from Elicit search

• n = 200 papers screened using: PALOMA-2 Trial Relevance, Patient Population, Clinical Outcomes, Intervention Specificity, Disease Population Specificity, Study Design Appropriateness
• n = 200 papers screened out
• n = 10 papers included for extraction

Results

Characteristics of Included Studies

The included publications comprised analyses from the PALOMA-2 trial, a phase 3 randomized controlled trial that enrolled 666 postmenopausal women with ER+/HER2- advanced breast cancer. Patients were randomized 2:1 to palbociclib plus letrozole (n=444) or placebo plus letrozole (n=222). Key eligibility criteria included no prior systemic therapy for advanced disease and performance status 0-2.

Efficacy Outcomes

Progression-Free Survival

Across all analyses, palbociclib plus letrozole demonstrated consistent improvement in PFS compared to placebo plus letrozole. In the primary analysis, median PFS was 24.8 months versus 14.5 months (HR 0.58, 95% CI 0.46-0.72, P<0.001). With extended follow-up of approximately 38 months, median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001).

• Analysis:
  • Follow-up: Not specified
  • Palbociclib + letrozole mPFS: 24.8 months
  • Placebo + letrozole mPFS: 14.5 months
  • HR (95% CI): 0.58 (0.46-0.72)
  • P-value: <0.001

Overall Survival

After a median follow-up of 90.1 months, median OS was 53.9 months (95% CI 49.8-60.8) with palbociclib plus letrozole versus 51.2 months (95% CI 43.7-58.9) with placebo plus letrozole (HR 0.96, 95% CI 0.78-1.18, one-sided P=0.34).

Objective Response and Clinical Benefit

In the intent-to-treat population, objective response was achieved by 44% of patients receiving palbociclib plus letrozole versus 35% receiving placebo plus letrozole. Among Japanese patients specifically, ORR was 46.4% (95% CI 27.5-66.1) versus 38.5% (95% CI 13.9-68.4), and clinical benefit rate was 75.0% (95% CI 55.1-89.3) versus 84.6% (95% CI 54.6-98.1).

Quality of Life

Patient-reported outcomes were assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-Breast) and EuroQol 5 dimensions (EQ-5D) questionnaires.

• QOL measure: Changes from baseline in QOL scores
• Between-arm difference: No significant changes from baseline, significant improvement in pain scores (-0.256 vs -0.098, P=0.0183)

Clinical Implications

The PALOMA-2 trial consistently demonstrated progression-free survival benefit with palbociclib plus letrozole across multiple follow-up analyses and patient subgroups, while overall survival did not reach statistical significance. This apparent discordance between PFS and OS outcomes merits mechanistic explanation.